## A1.12 Should psychosocial treatments be used in addition to pharmacological maintenance treatments?

**GRADE** evidence profile

| Author(s):             | Amato, Minozzi  |  |  |  |  |  |  |
|------------------------|---|--|--|--|--|--|--|
| Date:                  | 23/03/2006  |  |  |  |  |  |  |
| Question:              | Should psychosocial plus pharmacological maintenance treatments versus pharmacological maintenance treatments alone |  |  |  |  |  |  |
|                        | be used for opioid dependence?  |  |  |  |  |  |  |
| Patient or population: | Opiate dependent patients   |  |  |  |  |  |  |
| Settings:              | Outpatient  |  |  |  |  |  |  |
| Systematic review:     | Amato et al.; Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone |  |  |  |  |  |  |
|                        | for treatment of opioid dependence (CLIB 4, 2004) <sup>1257]</sup> .  |  |  |  |  |  |  |

| Quality assessment   |  |                                |   |                   | Summary of findings                        |   |  |   |  |              |         |  |
|--|--|--------------------------------|---|-------------------|--|---|--|---|--|--------------|---------|--|
|  |  |                                |   |                   | No of patients                             |   | Effect   |   | Quality                                      | Imp          |         |  |
| No.<br>studies   | Design   | Limitations                    | Consistency                                     | Directness        | Other<br>considerations                    | Psychosocial plus<br>pharmacological<br>maintenance<br>treatments | Pharmacological<br>maintenance<br>treatments alone | Relative<br>risk (RR)<br>(95% Cl)           | Absolute risk<br>(AR)<br>(95% Cl)            |              | ortance |  |
| Retention in treatment <sup>[247, 248, 249, 212, 250, 251, 252, 253]</sup> (Objective follow-up: 6-24 weeks <sup>a</sup> ) |  |                                |   |                   |  |   |  |   |  |              |         |  |
| 8ª   | Randomized<br>trials   | No<br>limitations <sup>b</sup> | No important inconsistency                      | No<br>uncertainty | None                                       | 228/296<br>(77%)  | 170/214<br>(79,4%)                                 | RR 0.94 <sup>c,e</sup><br>(0.85 to<br>1.02) | 50 less / 1 000<br>(120 less to 20<br>more)  | ⊕⊕⊕⊕<br>High | 7       |  |
| Use of opi   | Use of opiates <sup>[254, 156, 251, 252, 253]</sup> (Objective <sup>9</sup> follow-up: 6-32 weeks <sup>4</sup> ) |                                |   |                   |  |   |  |   |  |              |         |  |
| 5f   | Randomized<br>trials   | No<br>limitations <sup>h</sup> | No important inconsistency                      | No<br>uncertainty | None                                       | 70/187<br>(37,4%)   | 105/201<br>(52,2%)                                 | RR 0.69 <sup>i</sup><br>(0.53 to<br>0.91)   | 190 less / 1 000<br>(320 less to 50<br>less) | ⊕⊕⊕⊕<br>High | 7       |  |
| Retention in treatment at the end of follow-up <sup>125, 248, 256]</sup> (Objective follow-up: 4-48 weeks)                 |  |                                |   |                   |  |   |  |   |  |              |         |  |
| 3i   | Randomized<br>trials   | No<br>limitations <sup>k</sup> | No important inconsistency                      | No<br>uncertainty | None                                       | 105/163<br>(64,4%)  | 62/87<br>(71,3%)                                   | RR 0.90 <sup>c</sup><br>(0.76 to<br>1.07)   | 70 less / 1 000<br>(190 less to 50<br>more)  | ⊕⊕⊕⊕<br>High | 7       |  |
| Abstinent at the end of follow-up <sup>[248,256]</sup> (follow-up: 1-12 months)  |  |                                |   |                   |  |   |  |   |  |              |         |  |
| 2'   | Randomized<br>trials   | No<br>limitations <sup>m</sup> | Important<br>inconsistency<br>(-1) <sup>n</sup> | No<br>uncertainty | Imprecise or sparse data (-1) <sup>n</sup> | 44/70<br>(62,9%)  | 27/38<br>(71,1%)                                   | RR 0.88 <sup>c</sup><br>(0.67 to<br>1.15)   | 90 less / 1 000<br>(260 less to 90<br>more)  | ⊕⊕OO<br>Low  | 6       |  |

All outpatient and all conducted in USA All but 1 unclear allocation concealment, 1 inadequate; 2 double blind Fixed effect model Length of treatment b

d

Excluding the study with inadequate allocation concealment the result do not change All outpatient and all conducted in USA е

g

Based on urinalysis All with unclear allocation concealment, 1 double blind

Random effect model

All outpatient and all conducted in USA All with unclear allocation concealment, 1 double blind Both outpatient and both conducted in USA 1 double blind, 2 unclear allocation concealment m

n

Two studies with conflicting results